Resources
To search for clinical trials and detailed information on products in development, visit our Prevention Research & Development Database
Results
showing 1-10 of 1029
Letter of Support for Dr. Anthony S. Fauci
In support of Dr. Anthony Fauci, AVAC submitted a letter to the Committee on Homeland Security
& Governmental Affairs ahead of a Congressional hearing focused on the origins of COVID-19. This letter reiterates Dr. Fauci’s decades-long dedication to understanding the immunology and virology of HIV and outlines AVAC’s grave concerns that the continued politicization of science and targeted subpoenaing of public servants like Dr. Fauci will have a chilling effect on public health and research.
The Persistence Paradigm: Ensuring the Longevity of Health Equity Research
In these exceptional times, how is health equity research faring? What can we collaboratively do to sustain and continue this important work which is so critical to supporting healthy communities and an HIV response? How can academia and community...
AVAC Infographics for AIDS 2026
For those presenting at AIDS 2026, AVAC’s latest infographics on the research and development pipeline, prevention options, and the impact of US funding cuts can be accessed here. We hope these are useful for presentations and discussions at the conference and beyond.
Alimatravir (MK-8527) Licensing Timeline
This timeline demonstrates the speed of generic licensing for alimatravir (MK-8527) compared to lenacapavir (LEN) and cabotegravir (CAB).
Prevention Option:
Years Ahead in HIV Prevention Research: Time to Market
This timeline shows the potential time points when the next-generation of HIV prevention options might find their way into new programs.
Prevention Option:
Lenacapavir Implementation Studies
Ongoing and planned implementation studies for the lenacapavir as of July 2026.
Prevention Option:
Injectable PrEP Regulatory Approvals
This graphic tracks regulatory approvals for injectable Cabotegravir and Lenacapavir for PrEP as of July 2026.
HIV Prevention Pipeline: Products to Watch
From the People’s Research Agenda, this graphic tracks the pipeline of potential new HIV prevention options across broadly neutralizing antibodies, preventive vaccines, pre-exposure prophylaxis, and multipurpose technologies.
Prevention Option:
Potential Lenacapavir Supply, 2026-28
Lenacapavir has the potential to reach millions — and the momentum is building. Using the current oral PrEP market as a baseline, this graphic estimates what demand for LEN could look like through 2028 and shows how current donor commitments stack up against that opportunity.
Prevention Option:
Lenacapavir Regulatory Approval
Regulatory approvals, pending decisions, and appeals as of July 2026.
Prevention Option:
showing 1-10 of 1029